Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Friedrich Maritsch"'
Autor:
Friedrich Maritsch, Ingeborg Cil, Colin McKinnon, Jesse Potash, Nicole Baumgartner, Valérie Philippon, Borislava G. Pavlova
Publikováno v:
BMC Medical Ethics, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Sharing anonymized/de-identified clinical trial data and publishing research outcomes in scientific journals, or presenting them at conferences, is key to data-driven scientific exchange. However, when data from scientific publica
Externí odkaz:
https://doaj.org/article/7bf20aead1dc4484a2a5a83baf687c13
Autor:
Paul A. Tambyah, Hartmut J. Ehrlich, Kwok-Yung Yuen, David S.C. Hui, P. Noel Barrett, Helen M. L. Oh, Alexandra Loew-Baselli, Sandor Fritsch, Annelies Wilder-Smith, Friedrich Maritsch, Gerald Aichinger, Maikel V. W. van der Velden, Otfried Kistner, Borislava G. Pavlova
Publikováno v:
Vaccine. 30:329-335
A successful vaccine development strategy for areas with clustered H5N1 events requires conduct of vaccine trials in potentially non-naive subjects and evaluation of post-vaccination responsiveness. An open-label, randomized, phase I/II study therefo
Autor:
Ortrun Obermann-Slupetzky, Borislava G. Pavlova, Friedrich Dorner, Sandor Fritsch, Alexandra Loew-Baselli, Eva Maria Poellabauer, P. Noel Barrett, Ingeborg Cil, Hartmut J. Ehrlich, Friedrich Maritsch
Publikováno v:
Vaccine. 22:217-223
Two clinical studies were conducted to identify the optimal dose of a modified tick-borne encephalitis (TBE) vaccine (FSME-IMMUN "new") in adults. A prospective, randomised, phase II, double-blind dose-finding study with the FSME-IMMUN "new" vaccine
Autor:
Otfried Kistner, Herwig Kollaritsch, Sandor Fritsch, P. Noel Barrett, Friedrich Maritsch, Thomas R. Kreil, Borislava G. Pavlova, Alexandra Loew-Baselli, Gerald Aichinger, Fritz Pinl, Markus Müller, Daniel Portsmouth, Markus Zeitlinger, Hartmut J. Ehrlich, Bernhard Schmitt
Publikováno v:
Vaccine. 30(30)
Background Immune responses to novel pandemic influenza vaccines may be influenced by previous exposure to antigenically similar seasonal strains. Methods An open-label, randomized, phase I/II study was conducted to assess the immunogenicity and safe
Autor:
Borislava G. Pavlova, Sandor Fritsch, Eva Maria Pöllabauer, Hartmut J. Ehrlich, Rudolf Angermayr, Jael Bosman, Barbara Valenta, P. Noel Barrett, Peter Harmacek, Roman Prymula, Alexandra Löw-Baselli, Friedrich Maritsch, Clair L. Firth, Wolfgang Draxler
Publikováno v:
Vaccine. 28(29)
TBE vaccination strategies capable of inducing strong paediatric immunogenicity and acceptable reactogenicity are still under evaluation. This single-blind, multi-center, randomized, controlled, phase III clinical study compared the immunogenicity an
Autor:
Eva Maria Pöllabauer, Alexandra Löw-Baselli, Borislava G. Pavlova, Friedrich Maritsch, Sandor Fritsch, Manuela Koska, P. Noel Barrett, Hartmut J. Ehrlich, Clair L. Firth
Publikováno v:
Vaccine. 28(29)
Two dose-finding studies and one open label safety study with a paediatric FSME-IMMUN formulation were conducted in children and adolescents aged 1-15 years (N=3697). The 1.2 microg antigen dose was identified as the optimal dose, inducing high seroc
Autor:
Helen M. L. Oh, P. Noel Barrett, Greg Berezuk, Eva Maria Pöllabauer, Hartmut J. Ehrlich, Alexandra Löw-Baselli, Markus Müller, Borislava G. Pavlova, Maikel V. W. van der Velden, Emanuele Montomoli, Friedrich Maritsch, Paul A. Tambyah, Markus Zeitlinger, Otfried Kistner, Sandor Fritsch
Publikováno v:
The Journal of infectious diseases. 200(7)
Novel strategies are required to provide rapid vaccine coverage in the event of an influenza pandemic. A phase I/II dose finding/ formulation study was performed with a whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen) to evaluate s
Autor:
Alexandra Loew-Baselli, Eva-Maria Poellabauer, P N Barrett, Sandor Fritsch, M Krammer, Friedrich Maritsch, P Harmacek, R Konior, Borislava G. Pavlova, Hartmut J. Ehrlich
Publikováno v:
Vaccine. 24(24)
A prospective, randomised, multicentre, single-blind phase 3 study was performed to assess the safety of a vaccination schedule consisting of two vaccinations (21-35 days apart) with the tick-borne encephalitis (TBE) vaccine FSME-IMMUN "adults" (five